BioStock: AdjuTec Pharma to start phase I trial with APC148

Adjutec is set to start its phase I clinical trial for the enzyme inhibitor APC148, marking a significant milestone for the company. The trial begins September 18 with CTC in Uppsala and will focus on assessing the candidate’s safety. With this step, AdjuTec moves from years of preclinical research into clinical-stage development, targeting the global issue of antibiotic resistance.

Read the full article at biostock.se:

https://www.biostock.se/en/2024/09/adjutec-pharma-to-start-phase-i-trial-with-apc148/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se